Lynparza is currently approved in mCRPC for a broad HRR-mutated patient population who have progressed on an NHA recommended by NCCN Clinical Practice Guidelines® In Oncology 1-3
1.de Bono J et al. Olaparib for metastatic castration resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102.
2. LYNPARZA. Summary of product characteristics.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) for Prostate Cancer V.1.2023.National Comprehensive Cancer Network, inc. 2023. All right reserved. Available at NCCN.org. Accessed Sept. 16. 2022
Date of Preparation: NOV 2022
For Adverse Events, Please contact AZ Patient Safety Team through any of the channels below: Tel: +966112249235
ksa.ae@astrazeneca.com
For Medical Information Requests, Please contact AZ Medical Information Team through any of the channels below: medinfo-ksa@astrazeneca.com
For medical information:
Medinfoksa@astrazeneca.com
Al - Nakhal Tower - Floor 13th - Ath Thumamah Road
Al Sahafa District. 7198 Unit No. 20 Riyadh 13315 - 3642
Tel: +966(011)22 492 00; Fax: +966(011)22 492 92
For Adverse Event reporting please contact: +966 112249235
Or email: ksa.ae@astrazeneca.com
SA-5977